Background Orally administered bisphosphonate drugs (ie, alendronate, etidronate,
risedronate) can reduce the risk of vertebral fracture. However, only alendronate and …

Objectives The aim of this study was to investigate the association between bisphosphonate
use and the risk of new fracture in a nationwide cohort of individuals with previous hip …

The comparative effectiveness of alendronate and risedronate has received limited
evaluation. Among 19,063 new users of bisphosphonates, risedronate users had a higher …

Introduction Randomized clinical trials have shown that risedronate and alendronate reduce
fractures among women with osteoporosis. The aim of this observational study was to …

This observational study showed that after 2 years, both risedronate and alendronate
lowered the risk of hip and nonvertebral fractures compared with patients filling in a single …

In postmenopausal women, the efficacy of bisphosphonates on hip fracture risk is not clear.
This Bayesian meta‐analysis quantitatively reviewed data from 12 randomized clinical trials …

Objectives To evaluate the association between the long-term use of bisphosphonates and
the risk of hip fracture compared to never use among women aged 65 years or older. Design …

This meta-analysis and systematic review investigated the efficacy of bisphosphonates on
the incidence of hip fracture (IHF) in patients of different ages with osteoporosis or …

There are differences in the risk profile of patients prescribed alendronate, risedronate, or
ibandronate. Observed reductions in fracture incidence over time suggest that the …

The aim of this study was to investigate the effect of bisphosphonates on preventing
osteoporotic hip fracture in patients with or without prior major osteoporotic fracture …